Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT00378209Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2006
- Primary completion
- Oct 2012
- Countries
- 1
- Sponsor
- Dana-Farber Cancer Institute
- Modality
- Modified Peptides, Orthosteric Ligands
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Proportion of Patients Alive and Without Progressive Disease at 6 months. Started Aug 2006; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
lenalidomide, dexamethasone, bortezomib combination
Combination of Bortezomib, Lenalidomide, and Dexamethasone.
03
Who it enrols
Patients with relapsed or relapsed/refractory multiple myeloma (1-3 prior lines) with adequate organ function and no severe neuropathy.
04
Endpoints
Primary
Proportion of Patients Alive and Without Progressive Disease
Secondary
Objective Response Rate
Duration of Response
Progression Free Survival
Overall Survival
Beyond the preview
Go deeper on NCT00378209.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378209.